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Chapter 14
Droplet Digital PCR for Minimal Residual Disease Detection
in Mature Lymphoproliferative Disorders
Daniela Drandi, Simone Ferrero, and Marco Ladetto
Abstract
Minimal residual disease (MRD) detection has a powerful prognostic relevance for response evaluation and
prediction of relapse in hematological malignancies. Real-time quantitative PCR (qPCR) has become the
settled and standardized method for MRD assessment in lymphoid disorders. However, qPCR is a relative
quantification approach, since it requires a reference standard curve. Droplet digitalTM PCR (ddPCRTM)
allows a reliable absolute tumor burden quantification withdrawing the need for preparing, for each
experiment, a tumor-specific standard curve. We have recently shown that ddPCR has a good concordance
with qPCR and could be a feasible and reliable tool for MRD monitoring in mature lymphoproliferative
disorders. In this chapter we describe the experimental workflow, from the detection of the clonal molecular
marker to the MRD monitoring by ddPCR, in patients affected by multiple myeloma, mantle cell
lymphoma and follicular lymphoma. However, standardization programs among different laboratories
are needed in order to ensure the reliability and reproducibility of ddPCR-based MRD results.
Key words Minimal residual disease (MRD), Follicular lymphoma (FL), Mantle cell lymphoma
(MCL), Multiple myeloma (MM), Immunoglobulin heavy-chain gene (IGH), t(14;18) translocation,
t(11;14) translocation, BCL2/IGH, BCL1/IGH, Droplet digital PCR
1 Introduction
Minimal residual disease (MRD) monitoring in hematology is
defined as any approach aimed at detecting and possibly quantifying
residual tumor cells beyond the sensitivity level of routine imaging
and laboratory techniques. Whenever a patient achieves complete
clinical remission a number of different scenarios might actually
take place including full eradication of the neoplastic clone, long-
term persistence of quiescent or nonclonogenic or immunologi-
cally regulated tumor cells or persistence of clonogenic cells capable
of giving rise to a full clinical relapse within months or years. MRD
analysis is currently a valuable early predictor of outcome in several
lymphoid malignancies, having made a considerable impact on
clinical research. Actually, the persistence of detectable MRD after
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a successful treatment heralds the disease recurrence and thusMRD
monitoring might drive preemptive treatments, aimed at avoiding
or delaying the onset of clinical relapse [1–8].
Different technologies have been used for MRD study. Molec-
ular methods—including polymerase chain reaction (PCR), real-
time quantitative PCR (qPCR), and the most recently introduced
next-generation sequencing (NGS)—are widely employed for
MRD monitoring in acute lymphoblastic leukemia (ALL) and lym-
phomas [9–19], while multicolor flow cytometry (MFC) has a
major role for MRD detection in chronic lymphocitic leukemia
(CLL) and multiple myeloma (MM) [20–22]. Although nowadays
qPCR is a well-established tool for MRD monitoring in lympho-
proliferative disorders, it has the main disadvantage of relying upon
a serial dilution standard curve for target quantification. One of the
latest evolutions of PCR, droplet digital PCR (ddPCR), has intro-
duced several practical advantages, compared to qPCR, most nota-
bly its absolute quantification nature does not require a reference
standard curve [23–33]. Moreover, we have recently shown that
ddPCR has a good concordance with qPCR with respect to sensi-
tivity, accuracy, and reproducibility, in the context of MRD evalua-
tion in mature lymphoproliferative disorders [34]. The greater
applicability and reduced labor intensiveness, compared to qPCR,
recommend ddPCR as an attractive alternative method for MRD
assessment.
In this chapter, we firstly provide a technical roadmap for a
suitable clonal-specific tumor marker identification from circulating
tumor cells. Then we describe our ddPCR-based MRD detection
approach based on different target types: (1) the immunoglobulin
heavy chain gene rearrangement (IGH) for MM and mantle cell
lymphoma (MCL), (2) the BCL1/IGH fusion gene, derived from
the chromosomal translocation t(11;14), for MCL, and (3) the
BCL2-MBR/IGH gene, arising from the chromosomal transloca-
tion t(14;18), for follicular lymphoma (FL).
Finally, we point out that ddPCR prognostic value still needs to
be validated in the context of prospective clinical trials. Most
importantly, before entering into the clinical practice, the promise
of ddPCR, compared to qPCR andMFC, needs to be proved in the
context of standardization programs. It is part of the current activ-
ities of the Euro-MRD group, a division of the European Scientific
foundation for Laboratory Hemato Oncology (ESLHO), to test
and validate these ddPCR assay at the inter-laboratory level, as has
already been done several years ago for qPCR. Since this is currently
a work in progress, the ddPCR procedures described in this manu-
script are likely to be updated in the not too distant future.
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2 Materials
2.1 Lab Workflow
Requirements
PCR protocols need appropriate caution to safeguard from con-
taminations. This aspect is particularly important in ddPCR, in
which even a single contaminant molecule could be detected. To
avoid contamination it is crucial to use clean supplies (i.e., gloves,
racks, tubes, plates, etc.) and dedicated pipettes (see Note 1).
Therefore, before PCR experiment setup, verify the following
workspace availability to prevent the risk of DNA contamination:
l Pre-PCR zone: dedicated to mix preparation. Keep any DNA or
PCR products away from this area.
l DNA zone: dedicated to adding template and droplet genera-
tion. Placed in a room separate from the pre-PCR zone.
l Post-PCR zone: dedicated to PCR amplification, PCR product
analysis and droplet reading.
2.2 Instruments
and Software
1. Fume hood for agarose gel setup.
2. Vortexer and minicentrifuge.
3. Nanodrop UV-Vis spectrophotometer (Fisher Thermo Scien-
tific, Waltham, MA, USA).
4. Benchtop centrifuge with microplate carriers and
microcentrifuge.
5. Thermal Cycler with heated lid, i.e., T100 (Bio-Rad, Labora-
tories, Hercules, CA, USA) or thermal cycler with similar
characteristics able to reach a ramp rate of 2.5 C/s.
6. Horizontal electrophoresis apparatus and power supply
(2–300 V/4–500 mA output voltage/current range).
7. Digital camera or any gel documentation and imaging systems.
8. DNA Sequencing facility for Sanger sequencing analysis.
9. Thermomixer (i.e., Eppendorf ThermoMixer C).
10. QX100TM or QX200TM ddPCRTM System (Bio-Rad, Labora-
tories, Hercules, CA, USA).
11. PX1TM PCR plate sealer (Bio-Rad, Laboratories, Hercules,
CA, USA).
12. Multichannel pipettes and filtered pipette tips.
13. Chromas (free licenced software) for electropherogram
visualization.
14. IMGT/V-QUEST tool (www.imgt.org) for IGH genes
sequence analysis.
15. Blastn (www.blast.ncbi.nlm.nih.gov) for BCL2-MBR/IGH
and BCL1/IGH genes sequence analysis.
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16. Primerquest and Oligo Analyzer 3.1 tools (www.eu.idtdna.
com) or Primer3Plus (www.primer3plus.com) for forward
and reverse allele-specific oligonucleotide (ASO) primers and
probes design.
17. QuantaSoftTM ddPCR analysis software (Bio-Rad, Labora-
tories, Hercules, CA, USA).
2.3 Reagents
and Kits
2.3.1 Bone Marrow
(BM) and Peripheral Blood
(PB) Sample Processing
1. Erythrocyte lysis buffer (0.155 M NH4Cl, 10 mM KHCO3,
0.1 mM ethylenediamine tetraacetic acid (EDTA),
pH 7.2–7.4).
2. Genomic DNA (gDNA) extraction from circulating tumor
cells can be performed by different methods such as DNAzol
(Thermo Fisher Scientific, Waltham, MA, USA), NucleoSpin
Tissue (Macherey-Nagel, Bethlehem, PA, USA), or automated
systems, such as the Maxwell RSC (Promega, Madison, WI,
USA).
2.3.2 Tumor-Specific
Molecular Marker
Assessment
1. Forward and reverse consensus primers for IGH [16, 35, 36],
BCL1/IGH [11] and BCL2-MBR/IGH [9] PCR screening
and sequencing (Table 1).
2. PCR reagents: GoTaq Flexi (5 U/μL), 5 Green GoTaq Flexi
buffer, 25 mMMgCl2 (Promega, Madison, WI, USA), dNTPs
mix (2 mM) (nonspecific company), and nuclease-free water.
3. 1 TAE buffer (40 mM Tris–acetate, 1 mM EDTA, in distilled
water, pH 8.0).
4. Agarose gel (2%).
5. Ethidium bromide 1% or RealSafe staining solution (Durviz,
Spain).
6. 100 bp DNA mass ladder (i.e., φX174-HaeIII digest).
7. QIAquick gel extraction kit (Qiagen GmbH, Germany).
8. QIAquick PCR purification kit (Qiagen GmbH, Germany).
9. TOPO-TA cloning Kit (Thermo Fisher Scientific, Waltham,
MA, USA).
10. ImMedia AmpBlue and ImMedia AMPLiquid agar for IPTG/
X-gal plates and low-salt LB liquid medium for bacteria grow-
ing, respectively (Thermo Fisher Scientific, Waltham, MA,
USA).
11. Wizard Plus SVminipreps DNA purification System (Promega,
Madison, WI, USA).
12. gDNA (100 ng/μL) from a BCL2-MBR/IGH-positive cell
line (such as DOHH-2 or RL).
13. gDNA (100 ng/μL) from a BCL1/IGH-positive cell line
(such as JVM2).
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2.3.3 MRD Detection by
ddPCR
1. Forward and reverse allele-specific oligonucleotide (ASO) pri-
mers and probes for individual IGH regions and for BCL1/
IGH translocations. Consensus forward and reverse primers
and probes for BCL2-MBR/IGH. See Table 2 and Fig. 6.
2. 2 ddPCR Supermix for Probes (No dUTP) (cat. 186-3024),
DG8 cartridges (cat. 186-4008), DG8 gaskets (cat.
186-3009), ddPCR droplet generation oil for probes (cat.
186-3005), pierceable foil heat seals (cat. 181-4040), ddPCR
droplet reader oil (cat. 186-3004) (Bio-Rad Laboratories, Her-
cules, CA, USA).
Table 1
Primer sequences for IGH, BCL1/IGH and BCL2-MBR/IGH screening by PCR or nested-PCR. Reverse
primers are italicized
Target Primer Sequence (50-30)
IGH VH1Fs CAGGTGCAGCTGGTGCARYCTG
VH2Fs CAGRTCACCTTGAAGGAGTCTG
VH3Fs GAGGTGCAGCTGGTGSAGTCYG
VH4aFs CAGSTGCAGCTGCAGGAGTCSG
VH4bFs CAGGTGCAGCTACARCAGTGGG
VH5Fs GAGGTGCAGCTGKTGCAGTCTG
VH6Fs CAGGTACAGCTGCAGCAGTCAG
VH1D CCTCAGTGAAGGTCTCCTGCAAGG
VH2D TCCTGCGCTGGTGAAAGCCACACA
VH3D GGTCCCTGAGACTCTCCTGTGCA
VH4aD TCGGAGACCCTGTCCCTCACCTGCA
VH4bD CGCTGTCTCTGGTTACTCCATCAG
VH5D GAAAAAGCCCGGGGAGTCTCTGAA
VH6D CCTGTGCCATCTCCGGGGACAGTG
JHD ACCTGAGGAGACGGTGACCAGGGT
VH1-FR2 CTGGGTGCGACAGGCCCCTGGACAA
VH2-FR2 TGGATCCGTCAGCCCCCAGGGAAGG
VH3-FR2 GGTCCGCCAGGCTCCAGGGAA
VH4-FR2 TGGATCCGCCAGCCCCCAGGGAAGG
VH5-FR2 GGGTGCGCCAGATGCCCGGGAAAGG
VH6-FR2 TGGATCAGGCAGTCCCCATCGAGAG
VH7-FR2 TTGGGTGCGACAGGCCCCTGGACAA
JHC CTTACCTGAGGAGACGGTGACC
BCL1/IGH BCL1-P2 GAAGGACTTGTGGGTTGC
BCL1-P4 GCTGCTGTACACATCGGT
JH3 ACCTGAGGAGACGGTGACC
BCL2-MBR/IGH MBR2 CAGCCTTGAAACATTGATGG
JH3 ACCTGAGGAGACGGTGACC
MBR3 TATGGTGGTTTGACCTTTAG
JH4 ACCAGGGTCCCTTGGCCCCA
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3. 96-well PCR plates and optical adhesive films or 0.2 mL strip
tubes with cups (used for mix preparation and collection before
droplets generation).
4. Scotch tape.
5. Hard-shell high-profile 96-well semiskirted PCR plates (cat.
0030 128.575) (Eppendorf, Hamburg, Germany).
6. gDNA (100 ng/μL) from a BCL2-MBR/IGH-positive cell
line (such as DOHH-2 or RL).
7. gDNA (100 ng/μL) from buffy coat (BC), pooled from 5 to
10 healthy donors, to use as negative control in IGH and
BCL1/IGH ddPCR reactions.
8. gDNA (100 ng/μL) from a BCL2-MBR/IGH-negative sam-
ple as MCF-7 human breast cancer cell line, a chemotreated
patients or any subject previously assessed by PCR to be BCL2-
MBR/IGH negative, since this translocation can be also pres-
ent in healthy donors without lymphoma [37].
Table 2
Primers and probes sequences used in MRD based ddPCR
Target Oligos type NAME 50-SEQUENCE-30
IGH PRIMER forward Pt code-F Pt specific sequence derived from CDR2 region
PRIMER reverse Pt code-R Pt specific sequence derived from CDR3 region
LVH1 GCACAGCCTACATGGAGCTGAGCAG
MVH2 ACCACCTGGTTTTTGGAGGTGTCCTT
LVH3 TCCTCGGCTCTCAGGC
MVH3TER CTCTGGAGATGGTGAATCGGC
PROBES MVH4 TGTCTGCAGCGGTCACAGA
MVH4TER TGTCCGCGGCGGTCACAGA
LVH5 CTTCAGGCTGCTCCACTGCAGGTAG
LVH1bis TACATGGAGCTGAGCAGCCTGA
LVH4 CAACCCCTCCCTCAAAGAGTC
VH3DD3 GATTCACCATCTCCAGAGACA
DVH4 TGTTTGCGGCGGTCACAGA
VH3MG CGGCCCCTCACGGAGTCT
PRIMER forward Pt code-F Pt specific sequence derived from “N” region
BCL1/IGH PRIMER consensus JH3 ACCTGAGGAGACGGTGACC
PROBES JH1-4-5 ACCCTGGTCACCGTCTCCTCAGGTG
JHDD1 ACGTCTGGGGCAAAGGGACCACGG
JHG2 CGATCTCTGGGGCCGTGGCAC
BCL2-MBR/
IGH
PRIMER forward Mbr2/Q CTATGGTGGTTTGACCTTTAGAG
PRIMER reverse JH32-short CCTGAGGAGACGGTGACC
PROBE BCL2 CTGTTTCAACACAGACCCACCCAGAG
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3 Methods
Methods described below provide a technical support for clonal-
specific tumor marker identification and ddPCR-based MRDmon-
itoring in MM, MCL and FL. Figure 1 shows the schematic experi-
mental workflow, for each disease, summarizing the steps from
sample acquisition through patient’s unique tumor marker deter-
mination to MRD quantification by ddPCR.
3.1 Bone Marrow
and Peripheral Blood
Samples Processing
1. For sample collection, the use of sodium citrate or EDTA is
preferred (see Note 2) over Heparin.
2. Resuspend blood samples in erythrocyte lysis buffer (NH4Cl)
(dilute BM 1:4 and PB 1:2). Leave blood tubes for 15 min at
room temperature (lying flat in the dark) then centrifuge for
10 min at 450  g at room temperature. Discard the superna-
tant wash in NH4Cl and centrifuge for 10 min at 450  g at
room temperature. Remove supernatant, resuspend cell pellets
in PBS or 0.9% NaCl count and dispense 5–10  106 cells in
1.5 mL tubes; centrifuge for 1 min at 13000  g and discard
supernatant. Cells can now be stored indefinitely, as dried
pellets, at 80 C for further gDNA extraction.
3. Perform gDNA extraction with a commonly used method
or kit.
4. Estimate the gDNA quality and concentration before experi-
mental use (see Note 3).
5. Prepare 200–300 μL of 100 ng/μL stock solution and store at
20 C (see Note 4).
3.2 Tumor-Specific
Molecular Marker
Identification
Be aware that samples containing <5% of tumor cells present a
lower rate of success in marker identification (especially for IGH
sequencing) by Sanger sequencing. Therefore, diagnostic samples
containing a high percentage of tumor cells (>5%) are required.
Multiple strategies to obtain the tumor-specific marker are
currently available [15–17].
Here we present a PCR based approach (Fig. 2a–c), established
as previously published [9, 11, 36], to identify and to direct
sequencing:
1. IGH rearrangements in MM and MCL.
2. BCL1/IGH gene translocation, in MCL (if IGH rearrange-
ment is not successfully identified).
3. BCL2-MBR/IGH gene translocation, in FL.
3.2.1 IGH Clonal
Rearrangement Screening
at Baseline
1. The strategy used for IGH screening adopts three sets of
consensus forward primers (VH-FS, VH-D and VH-FR2)
derived from framework regions (FR1, FR2), each set is
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combined separately with the appropriate JH antisense consen-
sus primer (JHD or JHC; Fig. 2a). We suggest performing a
first PCR screening by individually combining each of the
VH-FS family primers with the reverse JHD primer. In case
of no amplification, switch to the VH-D and then to VH-FR2
set of primers combined one-at-a-time with the JHD or JHC
primers, respectively (Table 1) [10, 16, 35, 36].
2. In the Pre-PCR zone, prepare a 45 μL PCR mix solution in
0.2 mL tubes. Figure 3 shows an example of how to prepare the
PCR reaction mix for the IGH screening with VH-FS primers.
3. In the DNA zone, add 5 μL of gDNA (100 ng/μL) in each of
the patient and control tubes. Before adding the gDNA to the
mix, ensure that the DNA is thoroughly mixed. Vortex, spin
down, and then pipet the gDNA sample up and down a few
times.
V D J
FR1 FR2 FR4FR3CDR1 CDR2L CDR3
Rearranged IgH (VDJ)
A
B
C
MBR2
MBR3 JH4
JH3
#18q21 BCL2 GENE (EXON3) IGH GENE # 14q32 (JH SEGMENT)
BCL1-P2
JH3
JH3
#11q13 BCL1 GENE (UPSTREAM MTC SITE) IGH GENE # 14q32 (JH SEGMENT)
BCL1-P4
VH-FS VH-D
JHCVH-FR2
JHD
Fig. 2 Schematic representation of PCR strategies used, for marker identification, for: (a) IGH rearrangements
screening in MM and MCL, (b) BCL1/IGH gene translocation, in MCL and (c) BCL2-MBR/IGH gene translocation
in FL, performed on diagnostic sample. IGH rearrangement derives from the combination of V-(D)-J segments
that code for the variable domains of the IGH molecules. In both BCL1/IGH and BCL2-MBR/IGH translocations
the IGH locus at 14q32.3 is involved and the BCL1 gene from 11q13 and BCL2 region from 18q21 are
translocated, respectively, to the IGH locus. IGH gene regions: L (leader), F (framework), CD (complementary
determining)
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4. Perform PCR with thermal cycling conditions and control
DNA’s as shown in Fig. 3.
5. Analyze the amplification product by running 10 μL of PCR
product on a 2% agarose gel, together with a DNA molecular
weight marker (see Note 5).
6. Visualize with UV light and capture the image by a digital
photo camera, in order to have documentation of the experi-
ment result (see Note 6). The IGH product size must be
between 300 and 500 bp.
7. In case of lack of amplification, repeat the PCR using a new set
of primers (i.e., VH-D and VH-FR2; see Note 7). If no ampli-
fication is observed with all three sets of primers, no MRD
analysis based on this molecular marker can be performed. In
case of MCL sample, move to Subheading 3.2.3 for BCL1/
IGH screening. In case of MM, the patient is marked as “IGH
negative: no marker available for MRD analysis”.
8. If the PCR product appears on the gel as a unique band, the
whole volume of amplified gDNA can be directly purified by
“QIAquick PCR purification kit,” following the manufac-
turer’s instructions. Otherwise, use the “QIAquick gel extrac-
tion kit.” In this case, DNA containing the proper amplification
band must by sliced from the gel, weighed on a scale, put in a
Reagents  1 Reaction (µl)
Sample gDNA code VH-F primer
dNTPs mix (2mM) 5 1 CTR+ gDNA or PL VH- specific
5x GoTaq Flexi Green Buffer 10 2 pt1 VH-FS1
MgCl2 (20mM) 5 3 pt1 VH-FS2
GoTaq Flexi 5U/µl (Promega) 0,25 4 pt1 VH-FS3
VH-FS (10pmol/µl) 1 5 pt1 VH-FS4a
JHD (10pmol/µl) 1 6 pt1 VH-FS4b
H2O 22,75 7 pt1 VH-F5
TOT mix 45 8 pt1 VH-F6
9 CTR- H2O all VH-F primers
gDNA 5
TOT 50
Initial denaturation: 94°C for 1 minute
Denaturation: 94°C for 30 seconds
Annealing: 62°C for 30 seconds repeated for 33 cycles
Extension: 72°C for 30 seconds
Final extension: 72°C for 10 minutes
IGH REARRANGEMENT
Fig. 3 PCR reaction mix and setup for the IGH screening with VH-FS primers. The IGH strategy adopts three
sets of consensus forward primers (VH-FS, VH-D, and VH-FR2) each set combined separately with the
appropriate JH antisense consensus primer (JHD or JHC). The PCR reaction mix here described combines
each of the VH-FS family primers with the reverse JHD primer. In case of no amplification or no monoclonal
IGH gene identification, the VH-D and then the VH-FR2 set of primers are combined one-at-a-time with the
JHD or JHC primers, respectively, see Table 1 for primers sequence. (VH-FS (VH-FS forward primer), gDNA
(genomic DNA), CTR+ (positive control), PL (plasmid), CTR- (negative control), pt (patient)
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1.5 mL microcentrifuge tube and stored at 4 C until the
extraction. (It is recommended to store no longer than for
1 day).
9. Direct Sanger sequencing from both strands, with the same
primers used in the successful PCR reaction described above
can now be performed. To check the validity of the sequence,
visualize the electropherogram by “Chromas” or other known
software (see Note 8).
10. In case of identification of a monoclonal sequence, proceed
with sequence analysis using the IMGT/V-QUEST database
(www.imgt.org). IMGTallows you to verify that your sequence
is an IGH and to display the gene regions where primers and
probe must be depicted (Subheading 3.3.1).
11. If the sequence is polyclonal, proceed with IGH cloning (Sub-
heading 3.2.2; see Fig. 1). This circumstance is more frequent
in MM samples, mostly due to their high rate of somatic
hypermutation, which may significantly reduce primer
efficiency.
3.2.2 Cloning of Patient-
Specific Rearrangement
To be used when direct Sanger sequencing does not allow identifi-
cation of a clonal sequence. For MCL patients, cloning should be
performed only in cases where both IGH and BCL1/IGH have
been screened and a polyclonal sequence has been identified.
1. Set up the ligation reaction on ice using the TA-TOPO cloning
kit: Combine 1 μL of TA-TOPO Cloning vector, 1 μL of Salt
solution, 4 μL of fresh patient-specific PCR product. Mix
together well. Incubate at room temperature for 30 min and,
if not immediately used for bacterial transformation, store at
20 C.
2. Thaw competent E. coli (stored 80 C) on ice, add 3 μL of
ligation product to competent cells, shake gently and incubate
for 30 min, on ice.
3. Heat-shock at 42 C for 30 s on a Thermomixer (without
shaking) and immediately put on ice for 2 min.
4. Add 250 μL of S.O.C Medium (supplied with the TA-TOPO
cloning kit), incubate for 60 min at 37 C in a thermomixer
under vigorous shaking (800–1000 rpm).
5. Spread 50–70 μL of transformed cells on agar petri dish, previ-
ously prepared with “ImMedia Amp blue” (prepared following
the vendor’s instructions). Air-dry for few minutes. Incubate at
37 C overnight (see Note 9).
6. Grow up the transformed cells (10–15 white colonies) into
1.5 mL of “ImMedia Amp Liquid” incubating overnight at
37 C under vigorous shaking (800–1000 rpm) on a thermo-
mixer. The next day, perform a PCR amplification using 2 μL of
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the overnight grown transformed cells, adjusting the volume of
PCRmix with 25.75 μL of water, instead of 22.75 μL. In order
to verify the presence of the cloned rearrangement the same
primers, and the same conditions previously used at the screen-
ing, must be used. Run on a 2% gel and verify which plasmids
contain product with the desired molecular weight band.
7. Perform plasmid DNA isolation and purification (Wizard Plus
SV Miniprep DNA purification system, Promega, Madison,
WI) from those plasmids showing similar amplification size.
8. Check the sequence of at least ten different plasmids. Sequenc-
ing only one strand from the forward side is usually enough for
good sequence comparison. If an identical sequence shows up
in at least three different plasmids, this sequence can be consid-
ered to represent the tumor clone [12]. Then, proceed with
sequence analyses by IMGT (for IGH) or Blastn (for BCL1/
IGH) and the design of clone-specific primers and probe (see
Subheading 3.3.1).
3.2.3 BCL1/IGH
Translocation Screening at
Diagnosis
MCL patients not successfully screened for an IGH rearrangement
are then screened for the BCL1/IGH translocation, by a semi-
nested PCR approach (see Fig. 2b). This consists of a first PCR
amplification using a sense 50 primer (BCL1-P2) located in the
major translocation cluster (MTC) upstream of the BCL1 gene,
followed by a second PCR reaction performed with a sense 50
primer (BCL1-P4) located 43 bp downstream from the BCL1-P2
primer. Both amplifications employ an antisense 30 joining region
(JH3) consensus primer [11].
1. In the Pre-PCR zone, prepare a 45 μL mix solution in 0.2 mL
tubes, as shown in Fig. 4, using the 1st amplification primer
pair specified (BCL1-P2/JH3).
2. In the DNA zone, add 5 μL of gDNA (100 ng/μL). Before
adding the gDNA to the mix, ensure that the DNA is thor-
oughly mixed. Vortex, spin down, and then pipet the gDNA
sample a few times.
3. Run 1st round PCR under the conditions shown in Fig. 4.
4. Set up the 2nd round PCR: in the Pre-PCR zone, prepare a
48 μL mix solution as shown in Fig. 4, (adjusting the mix with
25.75 μL of water, instead of 22.75 μL), using the 2nd ampli-
fication primer pair (BCL1-P4/JH3).
5. In the post PCR-zone, add 2 μL of 1st amplification PCR
product.
6. Run the 2nd round PCR at the thermal cycling conditions
shown in Fig. 4.
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7. Follow the steps 5, 6, 8, and 9 described in Subheading 3.2.1.
BCL1/IGH PCR product size should be in the size range
between 100 and 300 bp (see Note 7).
8. If the sequence electropherogram is monoclonal, proceed with
sequence analysis using Blastn (www.blast.ncbi.nlm.nih.gov)
to verify the BCL1/IGH translocation sequence and proceed
with primers and probe design as described in Subheading
3.3.1, otherwise proceed with cloning as above (see Subheading
3.2.2).
3.2.4 BCL2-MBR/IGH
Translocation Screening at
Diagnosis
A number of variant translocations involving the BCL2 gene have
been described; however only MBR translocations (Major Break-
point Region), and to a lesser extent mcr (minor cluster region)
translocations, have been extensively exploited for MRD analysis
[6, 9, 38]. Thus, only a subset of FL patients, ranging from 50% to
65%, can currently be assessed using the BCL2/IGH nested PCR
approach [6, 39, 40]. The procedure here described is focused only
on the most common BCL2-MBR/IGH translocation (Fig. 2c).
However, if no clonal signal is observed for the BCL2-MBR/IGH
translocation, we suggest trying with other primers sets for minor
breakpoint region detection [38].
Reagents  1st round PCR (µl) 2nd round PCR (µl)
Sample gDNA code
dNTPs mix (2mM) 5 5 1 CTR+ JVM-2 (10-2)
5x GoTaq Flexi Green Buffer 10 10 2 Pt1
MgCl2 (15mM) 5 5 … …
GoTaq Flexi 5U/ µl (Promega) 0.25 0.25 … Ptn
BCL1-MTC  (10pmol/µl) 1 1 n CTR- H2O
JH              (10pmol/µl) 1 1
H2O 22.75 25.75
TOT mix 45 48
gDNA 5 2
TOT 50 50
Primers BCL1-P2/JH3 BCL1-P4 /JH3
Denaturation: 94°C for 60 seconds
Annealing: 58°C for 30 seconds         repeated for 33 cycles (1st round PCR)
Extension: 72°C for 30 seconds         repeated for 30 cycles (2nd round PCR) 
Final extension: 72°C for 10 minutes
BCL1/IGH
Fig. 4 BCL1/IGH rearrengement reaction and setup. BCL1-MTC (forward primer, BCL1-P2 or BCL1-P4), JH:
reverse primer (JH3 or JH4), gDNA (genomic DNA), CTR+ (positive control), CTR- (negative control),
pt. (patient), JVM-2 (BCL1/IGH positive cell line)
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1. In the Pre-PCR zone, prepare a 45 μL mix solution, in 0.2 mL
tubes, as shown in Fig. 5, using the BCL2-MBR2/JH3
primer pair.
2. In the DNA zone, add 5 μL of gDNA (100 ng/μL). Before
adding the gDNA to the mix, ensure that the DNA is thor-
oughly mixed. Vortex, spin down, and then pipet the gDNA
sample few times.
3. Follow 1st round PCR thermal cycler conditions as shown in
Fig. 5 (27 cycles).
4. In the Pre-PCR zone, set up the 2nd round PCR: prepare a
45 μL mix solution, as shown in Fig. 5, using the BCL2-
MBR3/JH4 primer pair.
5. In the post PCR-zone, add 5 μL of 1st amplification product
and run the 2nd round PCR (Fig. 5).
6. Follow the steps 5, 6, 8, and 9 as described in Subheading
3.2.1. BCL2-MBR/IGH PCR product size should range
between 150 and 400 bp (see Note7).
7. Proceed with Blastn (www.blast.ncbi.nlm.nih.gov) to verify the
BCL2-MBR/IGH translocation sequence.
3.3 MRD Monitoring
by ddPCR
3.3.1 Clone-Specific
Primers and Probe Design
ddPCR monitoring is performed based on the nucleotide sequence
of the clonal tumor-specific marker. Here we propose one strategy
for marker identification albeit other approaches, as gene scanning
or next generation sequencing, are now available [16, 17].
The junctional “N” regions, located in IGH rearrangements
(Fig. 6a), as well as in the BCL1/IGH (Fig. 6b) and BCL2-MBR/
IGH rearrangements (Fig. 6c), represent a “fingerprint” of the
lymphoma cell, and therefore their correct characterization is cru-
cial for tumor-specific primers and probe design and for patient-
specific MRD monitoring by ddPCR.
Particularly for the IGH and BCL1/IGH gene rearrenge-
ments, based on the sequences of interest, primers and probe
should be designed following the widely known common recom-
mendations [12, 15] (i.e., optimal melting temperature
(Tm) between 57 and 62 C, primers length between 13 and
26 mer, % CG content between 30 and 70%, probes with a Tm
6–8 C higher than the primers etc.). Moreover, we suggest Pri-
merQuest and Oligo Analyzer 3.1 (www.eu.idtdna.com) or Pri-
mer3Plus (www.primer3plus.com) as helpful tools for assay
design and optimization.
Different primer and probe design strategies need to be per-
formed for each target:
1. The strategy for the IGH rearrangement-basedMRDmonitor-
ing, here described, is named “ASO primer” and consists in as
follows: based on the IGH sequence, tumor-specific primers
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are positioned on the most hypervariable areas located in the
IGH-V second and third complementary-determining region
(CDR2-CDR3), while the consensus probe is designed on the
most constant FR3 region (Fig. 6a) and can be employed for a
large proportion of patients [2, 7, 8, 12, 41] (seeNote 10). In
our ongoing MRD studies, we routinely and successfully use a
panel of consensus probes listed in Table 2 that are suitable for
a high proportion of patients. However, in cases with frequent
somatic mutations in the IGH gene rearrangements, a
completely sequence-based design of primers and probe is
recommended.
2. For BCL1/IGH primer and probe design (Fig. 6b): a forward
patient-specific ASO primer, depicted within the junctional
“N” insertion or overlapping the breakpoint in the BCL1
sequence and should be used in combination with the same
JH primer used in the seminested PCR for IGH screening
Reagents  1 Reaction  (ml)
dNTPs mix (2mM) 5 Sample gDNA code
5x GoTaq Flexi Green Buffer 10 1 CTR+ DOHH2 (10-2)
MgCl2 (20mM) 5 2 Pt1
GoTaq Flexi 5U/ ml (Promega) 0.25 … …
BCL2-MBR  (20pmol/ml) 1 … Ptn
JH               (20pmol/ml) 1 n CTR- H2O
H2O 22.75
TOT mix 45
gDNA (1st PCR) or 1st PCR product (2ndPCR)   5
TOT 50
1st PCR reaction
Denaturation: 94°C for 60 seconds
Annealing: 55°C for 60 seconds             repeated for 27 cycles   
Extension: 72°C for 60 seconds
Final extension: 72°C for 10 minutes
2nd PCR reaction
Denaturation: 94°C for 60 seconds
Annealing: 58°C for 60 seconds             repeated for 30 cycles   
Extension: 72°C for 60 seconds
Final extension: 72°C for 10 minutes
BCL2-MBR2/JH3
BCL2-MBR3/JH4
BCL2-MBR/IGH 
1st amplification
2nd amplification
Fig. 5 BCL2-MBR/IGH rearrengement reaction and setup. BCL2-MBR (forward primer, BCL2-MBR3 or BCL2-
MBR4), JH (reverse primer JH3 or JH4), gDNA (genomic DNA), CTR+ (positive control), CTR- (negative control),
pt (patient), DOHH2 (BCL2-MBR/IGH positive cell line)
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(JH3). In order to reach high specificity, the probe is posi-
tioned in the JH region adjacent to the forward primer. Since
the translocation involves different JH genes (JH1 to JH6),
probes are not consensus for all patients but are represented by
a panel of probes (Table 2), depending on the JH sequence
rearranged. In this manner, the same probe can be suitable for
different patients sharing the same JH gene (see Note 11).
3. For BCL2-MBR/IGH translocation (Fig. 6c) the strategy uses
consensus primer-probe, previously described [6, 40], univer-
sally suitable for different FL patients, making MRD analysis in
this type of lymphoma much cheaper and faster compared to
ASO primers approach (see Note 12).
3.3.2 ddPCR Reaction
Setup
Major concepts to be aware of, before planning a ddPCR
experiment:
1. No standard curve generation is needed for ddPCR experiment
setup, and therefore no determination of percentage of tumor
V D J
FR1 FR2 FR4FR3CDR1 CDR2L CDR3
Rearranged IgH (VDJ)
A
B
C
ASO 5’ JH3
#11q13 BCL1 GENE (UPSTREAM MTC SITE) IGH GENE # 14q32 (JH SEGMENT)
N
CONSENSUS 5’ MBR2/Q JH32-SHORT CONSENSUS 3’
#18q21 BCL2 GENE (EXON3) IGH GENE # 14q32 (JH SEGMENT)
NN
ASO 5’ ASO 3’probe
probe
probe
FAM
MGB OR BHQ1
N
Fig. 6 Schematic representation of strategies used for designing: (a) IGH, (b) BCL1/IGH, and (c) BCL2-MBR/IGH
primers and probes for MRD analysis by ddPCR. N (N region with target specific nucleotide insertion), IGH gene
regions: L (leader), F (framework), CD (complementary determining), all strategies use FAM or BHQ1 probes
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cell, by flow cytometry, is required. Tumor burden quantifica-
tion is calculated as number of copies of target in 1  105 cells
(corresponding approximately to 500 ng of gDNA).
2. As for any kind of PCR experiments, a positive control is
mandatory (seeNote 13). The majority of BM or PB diagnostic
samples for MCL contain less than 50% of tumor cells infiltra-
tion. However, in order not to waste precious diagnostic
gDNA and to avoid system overloading, in case of highly
infiltrated samples we suggest loading a 101 or even a 102
diagnostic gDNA dilution point as positive control.
3. Since nonspecific amplification can be observed, negative con-
trols are mandatory. Nonspecific amplification (buffy coat)
should be run in six replicates and no template control
(NTC) in triplicates, for each specific marker quantification.
4. As the load of less template will result in loss of sensitivity,
particular attention must be used in gDNA quantification of
follow-up samples. So far, no consensus has been reached on
reference gene usage. Thus, in the context of the Italian MRD
lymphoma network, supported by the Italian Lymphoma
Foundation (FIL), an ongoing study is currently evaluating
several reference genes to establish which is the more stable
and reliable for gDNA quality/quantity assay. In the meantime,
we suggest to test, especially for follow-up samples, a reference
gene (i.e., albumin or RNAseP) on 100 ng of gDNA, in only
one replicate, preferably in the same ddPCR reaction as the
target gene.
(a) In the Pre-PCR zone, prepare the 20 primer and probe
mix and the ddPCR reaction mix, as shown in Fig. 7 (see
Note 14).
(b) Dispense the reaction mix in one well, based on the num-
ber of technical replicates needed, as described in Fig. 7
(i.e., for 1 replicate 16.5 μL and for 3 replicates 49.5 μL of
mix).
(c) In the DNA zone, load the amount of gDNA (100 ng/μ
L) depending on the number of planned replicates per
well, as indicated in Fig. 7 (i.e., for 1 replicate ¼ 16.5 μL
of mix, add 5.5 μL of gDNA; for 3 replicates ¼ 49.5 μL
(16.5 3) of mix, add 16.5 μL (5.5 3) of gDNA). From
this well, 20 μL of mix will be taken for each replicate
droplet generation. To ensure that the gDNA is thor-
oughly mixed: vortex, spin down, and then pipet the
sample a few times before adding the gDNA to the mix
(see Note 15).
(d) Seal carefully the plate or the strips with optical adhesive
film or caps, mix and spin down briefly.
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(e) Proceed with droplet generation, loading 20 μL of reac-
tion mix and 70 μL of droplet generation oil into the
proper DG8 cartridge wells, following manufacturer’s
instruction (see Note 16).
(f) Transfer 40 μL of generated droplets to the hard-shell
high-profile, 96-well semiskirted PCR plates and seal
immediately with a strip of scotch tape.
(g) After all samples are loaded, remove the tape and seal with
a pierceable foil on PX1 PCR plate sealer (Bio-Rad,
Laboratories, Hercules, CA, USA). Run on thermocycler
using the default Bio-Rad thermal cycling protocol
(95 C, 10min; 94 C, x 30 s, and (optimized or gradient)
TmC x 1 min, for 40 cycles; 98 C for 10 min) adjusting
the Tm according to the ASO primers for MM and MCL
and to 59 C for BCL2-MBR/IGH (Fig. 7).
(h) Load the post-PCR 96-wells plate in the QX100-QX200
droplet reader.Before run on the droplet reader, PCR
plate can also be stored at 4 C, no longer than 24 h.
For data interpretation, MRD tumor burden quantification is
expressed as total copies of target gene generated by performing
Fig. 7 ddPCR reaction and setup
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the merge of replicates by QuantaSoft (Bio-Rad Inc.) (seeNotes 17
and 18). Examples of data quality and analysis, for each target, are
shown in Figs. 8, 9, and 10.
3.4 Final Remarks Recent advances in gene quantification strategies have led to
increased sensitivity and reduced variability and risk of contamina-
tion. ddPCR appears to be a feasible and attractive alternative
method for MRD assessment in lymphoproliferative disorders and
might complement or even substitute qPCR in routine clinical
laboratories. One milestone of MRD monitoring by qPCR has
been the multilaboratory standardization established by large coop-
erative efforts such as the Euro-MRD group (see Note 19). Cur-
rently ddPCR still has to undergo such a critical validation step.
However, considering the reduced labor intensiveness of the exper-
imental setup and the current robust structure of the interlabora-
tory quality control groups, we believe that ddPCR standardization
would be definitely easier and faster than qPCR. However, the real
advantages and predictive value of ddPCR still need to be further
investigated in the context of prospective clinical trials.
4 Notes
1. Keep PCR reagents in a room where template is not isolated or
stored. Use sterile filter tips for pipetting to minimize contam-
ination from aerosols. We suggest to verify the quality of tips
used for droplet loading or to use what recommended by
Bio-Rad in the instruction manual. We recommend having
separate pipettes and pipette tips for PCR setup, DNA loading,
droplet generation, and post-PCR. Moreover, we suggest to
regularly decontaminate PCR work areas (with 10% bleach) as
well as pipettes (under UV).
2. Based on personal experimental observations (unpublished
data), we suggest collecting samples in EDTA or sodium citrate
instead of Heparin.
3. For assessment of gDNA concentration, the NanoDrop
method is quite accurate. However, always check the absor-
bance spectrum and not only the concentration value.
260/230 and 260/280 ratios and the shape of the curve can
give you important information about your sample quality.
When measuring your gDNA on the NanoDrop, firstly ensure
that the DNA is thoroughly mixed, preferably using vortex and
pipetting several times. If amount of gDNA is below 100 ng/μ
L or 260/280 ratio is not 1.8–1.9, sample must be repurified.
4. We suggest to estimate gDNA concentration after 100 ng/μL
stock preparation and before any PCR reaction, especially if
sample is stored at 4 C.
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Fig. 8 MRD monitoring of IGH rearrengement in an MCL patient: ddPCR was performed with patient-specific
ASO primers and LVH5 probe. In each pannel samples are reported from diagnostic to last follow-up. (a) 1D
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5. Always include a DNAmolecular weight marker such as ϕX174
DNA, cleaved with Hae III, ranging from 72 to 1353 bps, to
check the correct PCR product size. We suggest to use the 5
GoTaqFlexi Green Buffer which allows loading the amplifica-
tion reaction directly onto the gel, without need of loading
buffer and which is compatible with “QIAquick PCR purifica-
tion kit.” Run the gel at 120 V for 15–20 min, or until the two
color dye markers are well separated on the gel. One percent
ethidium bromide can be substituted by RealSafe Nucleic acid
staining solution at the concentration suggested by the manu-
facturer (Durviz, S.L., Spain).
6. Each qualitative PCR reaction must include a positive control
(to verify the quality of amplification) and a “no template
control” (NTC) (to check for contamination). If the positive
control fails or in case of PCR contamination, if the NTC is
positive, review all the procedures and change all reagents.
7. In case of lack of amplification, but good performance of PCR
confirmed by positive control sample, always verify that you
have good sample gDNA quantity/quality by performing a
PCR reaction for a housekeeping gene (e.g., Albumin,
RNase P, and p53).
8. For electropherogram analysis “Chromas” is ideal for basic
analysis of sequences and has no multiple sequences alignment
capability. To create a sequence database for routinely checking
for sequence contaminations, we suggest to gather all the
sequences by a multiple sequence alignment software such as
free CLC sequences viewer software (http://www.clcbio.com).
9. The efficiency of the ligation is determined by the comparison
of the growth of the experimental versus negative control
plates. If problems with cloning are encountered, verify that:
(a) you used fresh PCR product for ligation, since TOPO-TA
cloning requires fresh PCR; (b) competent cells are stored
properly at 80 C, since they are very sensitive to

Fig. 8 (continued) plot for patient coded “166” shows: bone marrow (BM), peripheral blood (PB) at diagnosis
(DIA), and post therapy follow-up (FU) at three time points (FLK1, FU2, and FU3). A single threshold has been
set in between the highest amplitude value of BC and the positive control (DIA). (b) Plot for positive events
(shorter bars) and total droplets (taller bars) for each sample analysed. Of note one event occurs in one of the
BC replicates and it is omitted from the analysis since it shows to be a nonspecific signal (overly high
amplitude value 11.000, data not shown in plot A since outside the amplitude range for graphical). (c)
Representation of concentration in terms of copies/μL
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Fig. 9 MRD monitoring of BCL1/IGH translocation in an MCL patient: ddPCR performed with a patient-specific
ASO forward primer, JH1-4-5 probe and JH3 reverse primer. (a) 1D plot for patient samples at diagnosis
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temperature; (c) thermomixer temperature for heat-shock pro-
cedure is correct; (d) SOC medium has not been stored for
too long.
10. Different groups use an “ASO probe” approach, derived from
the Euro-MRD guidelines for ALL, a neoplasia that is not
affected by somatic hypermutation of IGH sequences. The
“ASO primer” approach has shown to be a more powerful
strategy in the context of B-cell lymphoproliferative disorders,
characterized by a variable mutational load of IGH rearrange-
ment [40]. Moreover, “ASO primer” strategy has the advan-
tage to be much cheaper since no patient-specific probes are
needed.
11. Within the Euro-MRD network, the Lymphoma MRD group
recently planned to compare the specificity of different strategies
for BCL1/IGH primers and probe design, for MRD monitor-
ing (24th Euro-MRD meeting, Zurich 6–7 November 2015).
12. Clonal BCL2-MBR/IGH translocation is quantified by
ddPCR with a consensus primer-probe system (Table 2) that
does not require information about the sequence. However,
we recommend to always check the BCL2-MBR/IGH
sequence at diagnosis, in order to confirm the patient’s specific
clone and for its further monitoring in follow-up samples, as
well as to monitor for possible contaminations.
13. With respect to qPCR, ddPCR has the advantage of being an
absolute quantification method. However, although a standard
curve is not needed, in each experiment a positive control is
required. For IGH rearrangements and BCL1/IGH based
ddPCR, each patient requires his own baseline (or positive)
sample as positive control, while for BCL2/IGH based ddPCR
reactions gDNA from DOHH2 cell line is used as positive
control. The annealing temperature for each ASO primer set
can be different. For ASO primers test, use a thermal gradient
(2 C from the calculated primers Tm) to optimize ddPCR
results. If the positive control shows positive droplets at greater
than one amplitude level (graphically represented by two
clouds in 2D droplet plots or 2 bands in 1D droplet plots),
the annealing temperature can be increased in order to improve
the specificity; alternatively new ASO primers must be designed
until a single positive cluster is achieved (and the concentration

Fig. 9 (continued) (BASELINE) and at three follow-up time points. A single threshold has been set in between
the highest amplitude value of BC and the positive control (b) Positive events (shorter bars) and total droplets
(taller bars) for each sample analysed (c) Representation of concentration in terms of copies/μL
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Fig. 10 MRD monitoring of BCL2-MBR/IGH translocation in follow-up samples from six FL patients: ddPCR
performed with consensus primers and probe (see Table 2). (a) 1D plot for diluted DOHH2 positive control cell
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is consistent over a range of temperatures) even while the
separation between negative and positive clusters may vary.
14. We observed that for all assays, final primer and probe concen-
trations of 500 nM and 200 nM, respectively, work properly in
the ddPCR reaction (for 25 μL of 20 probe primer mix: 1 μL
probe (100 μM), 2.5 μL each primers (100 μM), 19 μL H2O).
For ddPCR analysis, MGB or BHQ1 probes are required.
TAMRA probes must be avoided since they lead to high back-
ground and noisy signals. As shown in Fig. 7, we normally
prepare the ddPCR mix for a volume increased by 10% to be
sure to have enough reaction mix volume for each replicate,
and to not risk introducing air bubbles into the DG8 cartridges
when loading the samples.
15. A total of 500 ng of gDNA is loaded in each replicate. Be aware
that, depending on the DNA extraction protocol, gDNA can
be more viscous and this characteristic can affect droplet for-
mation. For this reason, in case of sticky DNA, it is essential to
use restriction enzymes to decrease the size of the input DNA.
We observed that 2 U/μL of restriction enzyme (HINFI)
directly added into the reaction mix are sufficient for a good
ddPCR performance and proper droplet generation. However,
before using the enzyme, verify that primers and probe
sequences will not be damaged. To prepare a ddPCR reaction
mix containing the enzyme, add 1.1 μL of 2 U/μL of enzyme
to the 22 μL of ddPCR reaction mix, adjusting properly with
water.
16. We suggest: (a) to load the 20 μL of ddPCR mix in to the DG8
cartridge using a multichannel pipet with filtered tips; (b) to
paying attention when removing the DG8 gasket and always
remove it from the NTC, or BC well position, to the positive
control sample; (c) to load the ddPCR reaction mix into the
cartridge always before the oil; (d) to transfer the 40 μL of
droplets/well to the hard-shell, high-profile, 96-well semi-
skirted PCR plates using a multichannel pipet with no filter
tips and immediately seal the wells with a scotch tape; (e) to

Fig. 10 (continued) line (first three replicates), six follow-up samples from FL patients (PT) (three replicates
each) and negative controls (MCF7 and NTC). Of note, three different gDNA samples form MCF7 cell line, (two
replicates each) had been used as negative control. Variabilty in negative droplets amplitude depends on
sample type and purity and only in one patient (PT13, wells E04-E06) it is between technical replicates.
Moreover, this assay uses consensus primers and probe for different patients and different amplitude could
represents differencies in assay efficiency. A single threshold has been set in between the highest value of
amplitude of the background and the positive control. (b) Positive events (shorter bars) and total droplets (taller
bars) for each sample analysed (c) Representation of concentration in terms of copies/μL
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load the technical replicates in different DG8 cartridges to
avoid losing a full sample reaction, due to technical error that
can happen during pipetting or the droplet generation proce-
dure; (f) to remove carefully, any bubble created into the DG8
cartridge “sample” well during sample loading.
17. If you find a contamination (positive events in the range of the
positive control amplitude) in your NTC sample: (a) replace all
reagents and thoroughly clean PCR preparation areas;
(b) check whether the probe is degraded, since free dye can
give rise to signal and/or high background.
18. Only replicates with more than 9000 droplets must be consid-
ered for the analysis. We define as MRD positive by ddPCR
those samples that have all positive replicates and negative
those that have all negative replicates. Based on the higher
variability observed at low target concentrations and applying
the Euro-MRD guidelines, cases showing alternatively positive
or negative replicates must be judged with caution, especially if
less than totally three positive events are detected in the three
technical replicates. In such a case, ddPCR of the sample
should be performed again on more replicates (at least six) to
see if the result appears consistent. One critical limitation of
qPCR is its drawback to providing a reliable target quantifica-
tion for a proportion of samples with tumor burden between
the sensitivity and the quantitative range of the method. Sam-
ples falling in this window of unreliable quantification, by
qPCR, are currently defined as “positive nonquantifiable”
(qPNQ). ddPCR showed to be able to partially recover these
qPNQ samples [34]. However, specific guidelines for data
interpretation still need to be established and the potential
advantages and predictive value of ddPCR results, expecially
for these cases, need to be further validated.
19. The Euro-MRD group, (http://www.euromrd.org) is com-
posed by international MRD-PCR laboratories, under the
umbrella of ESLHO consortium (European Scientific founda-
tion for Laboratory Hemato Oncology). Euro-MRD group is
responsible for developing of new strategies and techniques, as
well as for developing guidelines for the interpretation of
qPCR based MRD data and in the near future also for devel-
oping guidelines for ddPCR based MRD.
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